Addario Lung Cancer Medical Institute (ALCMI)
LightNews LightNews
banner
alcmi.bsky.social
Addario Lung Cancer Medical Institute (ALCMI)
@alcmi.bsky.social
160 followers 260 following 390 posts
The Addario Lung Cancer Medical Institute (ALCMI) is a non-profit international consortium comprised of over 25 of the world's premier oncology research institutions. We fund and support investigator-led lung cancer clinical trials.
Posts Replies Media Videos
alcmi.bsky.social
New partnership alert! Bristol Myers Squibb and Microsoft have formed a new strategic partnership to use FDA-cleared radiology AI to detect lung cancer earlier and at scale. #lungcancer
oncodaily.com/techology/br...
Bristol Myers Squibb and Microsoft Partner to Advance AI-Driven Early Lung Cancer Detection - OncoDaily
Bristol Myers Squibb and Microsoft Partner to Advance AI-Driven Early Lung Cancer Detection / AI in healthcare, AI in Radiology, Artificial Intelligence in
oncodaily.com
February 1, 2026 at 8:01 PM
alcmi.bsky.social
Tom Cunningham, PhD, at the University of Cincinnati Cancer Center, is targeting the PRPS enzyme complex as a therapeutic dependency in KRAS-mutated lung cancer, backed by a two-year, $150,000 Lung Cancer Research Foundation grant. #lungcancer
www.uc.edu/news/article...
Cancer Center investigator targets key enzyme complex to treat KRAS-mutated lung cancer
The University of Cincinnati Cancer Center’s Tom Cunningham has received a two-year, $150,000 grant from the Lung Cancer Research Foundation (LCRF) to test approaches to neutralize an enzyme complex...
www.uc.edu
January 31, 2026 at 2:02 PM
alcmi.bsky.social
A history of tuberculosis and chronic bronchitis increases lung cancer risk in people who have never smoked, according to a new systematic review. #lungcancer
pubmed.ncbi.nlm.nih.gov/41534708/
Associations between Prior Lung Diseases and Risk of Lung Cancer in Populations With No Smoking History: A Systematic Review and Meta-Analysis - PubMed
History of TB and CB were associated with increased lung cancer risk among populations with no smoking history. Future studies examining these associations should analyze more diverse populations and...
pubmed.ncbi.nlm.nih.gov
January 30, 2026 at 2:03 PM
alcmi.bsky.social
Christian Jobin, Ph.D., and Rachel Newsome, Ph.D., at UF Health Cancer Institute have identified a gut microbiota–derived metabolite, Bac429, that materially increases immunotherapy activity in lung cancer models and is now being advanced into a drug candidate. #lungcancer
Gut bacteria molecule boosts lung cancer treatment response - UF Health
GAINESVILLE, Fla. — UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to…
ufhealth.org
January 17, 2026 at 3:03 PM
alcmi.bsky.social
Catherine Sears, MD, and colleagues at Indiana University are linking impaired DNA repair to the shared biology of emphysema and lung cancer. #lungcancer
www.lung.org/blog/copd-lu...
New Research May Reveal Why Lung Cancer and COPD Overlap
Dr. Catherine Sears’ research seeks to change the way COPD and lung cancer are treated.
www.lung.org
January 16, 2026 at 3:02 PM
alcmi.bsky.social
Zoldonrasib just became the first investigational KRAS G12D targeted therapy in NSCLC to receive FDA Breakthrough Therapy Designation, based on Phase 1 monotherapy data from Revolution Medicines. #lungcancer
ir.revmed.com/news-release...
ir.revmed.com
January 15, 2026 at 3:03 PM
alcmi.bsky.social
Basal stem cells, not neuroendocrine cells, may be the initiating cell of origin for small-cell lung cancer, according to Trudy Oliver. #lungcancer
www.dukechronicle.com/article/duke...
www.dukechronicle.com
January 14, 2026 at 3:02 PM
alcmi.bsky.social
Olvi-Vec delivered durable systemic activity in platinum-relapsed lung cancer, with up to 85% tumor shrinkage reported by Genelux in interim trial data published by RTTNews. #lungcancer
www.nasdaq.com/articles/gen...
www.nasdaq.com
January 13, 2026 at 3:01 PM
alcmi.bsky.social
Six FDA approvals in December 2025 expanded the oncology toolbox across blood cancers, prostate cancer, lung cancer, and supportive care, as reported in Cure. #lungcancer
www.curetoday.com/view/fda-app...
FDA Approves Six New Cancer Therapies in December 2025 | CURE
The FDA approved six new therapies for blood, prostate and lung cancers and supportive care, expanding treatment options based on recent trials.
www.curetoday.com
January 12, 2026 at 3:05 PM
alcmi.bsky.social
Check this out! AstraZeneca is re-running Datroway in relapsed NSCLC with a biomarker-enriched phase 3 design that directly addresses the Tropion-Lung01 miss. #lungcancer
www.oncologypipeline.com/apexonco/dat...
Datroway’s Tropion-Lung01 do-over?
“I am very impressed - it has become my go-to platform”
www.oncologypipeline.com
January 11, 2026 at 3:01 PM
alcmi.bsky.social
A large-scale study from the Genetic Epidemiology of Lung Cancer Consortium, led by Yanhong Liu and published in the Journal of Thoracic Oncology, identifies rare, high-penetrance germline variants that materially elevate familial lung cancer risk. #lungcancer
www.jto.org/article/S155...
www.jto.org
January 10, 2026 at 3:00 PM
alcmi.bsky.social
Inflammation is emerging as a primary engine of progression in small cell lung cancer. #lungcancer
medicalxpress.com/news/2025-12...
Inflammation fuels one of the most aggressive forms of lung cancer
Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%. Despite this poor prognosis, SCLC is initially highly responsive to…
medicalxpress.com
January 9, 2026 at 3:03 PM
alcmi.bsky.social
Early-onset lung cancer incidence in the United States is falling overall, but not for lung adenocarcinoma in young Asian and Hispanic women, according to a new SEER-based analysis. #lungcancer
acsjournals.onlinelibrary.wiley.com/doi/abs/10.1...
Patterns of lung cancer incidence in adults diagnosed under age 50 in the United States, 2000–2021
Early-onset lung cancer incidence declined overall from 2000 to 2021, except for persistent or rising LUAD among Asian and Hispanic females, which implicates emerging non-tobacco risk factors and highlights the need for targeted prevention.
acsjournals.onlinelibrary.wiley.com
January 8, 2026 at 3:03 PM
alcmi.bsky.social
LEMS in small cell lung cancer remains under-recognized and frequently misattributed to treatment-related toxicity, as highlighted by our friend Dr. Jacob Sands, MD, in a recent OncLive commentary. #lungcancer
www.onclive.com/view/dr-sand...
Dr Sands on Challenges in the Diagnosis and Management of LEMS in SCLC | OncLive
Jacob Sands, MD, discusses challenges in the diagnosis and management of LEMS in patients with small cell lung cancer.
www.onclive.com
January 7, 2026 at 3:03 PM
alcmi.bsky.social
A new phase 3 report in the NEJM Group shows that adding platinum-pemetrexed chemotherapy to first-line osimertinib improves overall survival in EGFR-mutated advanced NSCLC. #lungcancer
www.nejm.org/doi/abs/10.1...
Copyright © 2026 Massachusetts Medical Society . All rights…
Copyright © 2026 Massachusetts Medical Society . All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.…
www.nejm.org
January 6, 2026 at 3:01 PM
alcmi.bsky.social
Amivantamab plus hyaluronidase-lpuj (Rybrevant Faspro) has just become the first and only subcutaneous EGFR-targeted therapy for EGFR-mutated NSCLC. #lungcancer
www.pharmacytimes.com/view/fda-app...
FDA Approves Amivantamab and Hyaluronidase-lpuj, Revolutionizing Lung Cancer Treatment With 5-Minute Subcutaneous Delivery | Pharmacy Times
FDA approves Rybrevant Faspro, a groundbreaking subcutaneous therapy for EGFR-mutated lung cancer, enhancing patient comfort and survival rates.
www.pharmacytimes.com
January 5, 2026 at 3:02 PM
alcmi.bsky.social
City of Hope thoracic surgeons are using the fluorescent imaging agent Cytalux (pafolacianine) to make lung nodules “glow in the dark,” improving intraoperative identification of cancerous lesions in patients undergoing lung nodule surgery. #lungcancer
www.cityofhope.org/hope-matters...
How Doctors Are Making Lung Nodules Glow in the Dark
Uterine fibroid embolization is a minimally invasive treatment for fibroids. Discover how the UFE procedure works and how it compares to other treatments.
www.cityofhope.org
January 4, 2026 at 3:00 PM
alcmi.bsky.social
The OncoPrism-NSCLC test has been validated as a superior predictive biomarker for immunotherapy benefit in advanced lung cancer according to new data from Cofactor Genomics and the PREDAPT trial. #lungcancer
www.cancernetwork.com/view/oncopri...
OncoPrism-NSCLC Test Predicts Key Clinical Outcomes in Lung Cancer | CancerNetwork
OncoPrism-NSCLC was found to be a predictive biomarker of immune checkpoint inhibitor benefit vs a general prognostic tool in patients with NSCLC.
www.cancernetwork.com
January 3, 2026 at 3:02 PM
alcmi.bsky.social
University of Michigan Rogel Cancer Center investigators have defined PP2A stabilization by the molecular glue RPT04402 as a new protein target to overcome KRAS-driven non-small cell lung cancer. #lungcancer
www.news-medical.net/news/2025121...
Study finds a new protein target against KRAS-driven non-small cell lung cancer
Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States.
www.news-medical.net
January 2, 2026 at 3:02 PM
alcmi.bsky.social
2026 is here, and the ALCMI team is ready to work! Together, we are accelerating the path from trial concept to launching active clinical trials. Wishing our entire community a productive and healthy New Year! #lungcancer
January 1, 2026 at 3:03 PM
alcmi.bsky.social
A multidisciplinary screening program at the University of Rochester Medical Center more than doubled lung cancer detection rates to 71.6% by integrating a specialized EHR algorithm across a 42-practice network. Findings were published in NEJM Group. #lungcancer
Multidisciplinary Screening Program Dramatically Improves Lung Cancer Detection | www.PhysiciansWeekly.com
A coordinated, EHR-driven screening program more than doubled lung cancer screening rates across a primary care network.
www.physiciansweekly.com
December 31, 2025 at 3:01 PM
alcmi.bsky.social
Stanford Cancer Institute researchers led by Summer Han, PhD, have shown that replacing pack-years with years smoked as the core eligibility metric can make lung cancer screening more accurate and more equitable across racial and ethnic groups. #lungcancer
Rethinking lung cancer screening to reduce disparities
Using years smoked instead of pack-years could make lung cancer screening more accurate and equitable, helping more high-risk patients get early detection.
med.stanford.edu
December 30, 2025 at 3:01 PM
alcmi.bsky.social
University of Michigan investigators at the Rogel Cancer Center report that a PP2A “molecular glue” can stabilize tumor suppressor PP2A complexes and overcome RAS/MAPK inhibitor resistance in KRAS-mutant non-small cell lung cancer. #lungcancer
www.uofmhealth.org/health-lab/m...
'Molecular glue' stabilizes protein that inhibits development of non-small cell lung cancer
University of Michigan researchers found a new protein target PP2A and developed a drug to treat non-small cell lung cancers that have KRAS mutations.
www.uofmhealth.org
December 29, 2025 at 3:01 PM
alcmi.bsky.social
UK researchers have shown that a single circulating lung cancer cell can be detected in a routine blood sample using Fourier Transform Infrared (FT-IR) microspectroscopy. #lungcancer
medicalxpress.com/news/2025-12...
MedicalXpress - Medical Supplies, Consumables and Reusables.
See How Much You Could Save, No Minimum Order Amount. We Accept Orders From GPs, The NHS, Private Companies And Members Of The Public.
MedicalXpress.co.uk
December 28, 2025 at 3:02 PM
alcmi.bsky.social
2025 marked a clear inflection point in NSCLC outcomes, pushing 5-year survival toward 30%, as highlighted in the 2025 year-in-review on NSCLC care in Physician's Weekly. #lungcancer
What Changed in Lung Cancer Care in 2025 | www.PhysiciansWeekly.com
This slideshow distills the year’s most practice-changing lung cancer developments into a single, accessible overview.
www.physiciansweekly.com
December 27, 2025 at 3:01 PM